Cardiac Failure Review最新文献

筛选
英文 中文
How to Implant His Bundle and Left Bundle Pacing Leads: Tips and Pearls. 如何植入他的束和左束起搏导线:提示和珍珠。
Cardiac Failure Review Pub Date : 2021-08-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.04
Shunmuga Sundaram Ponnusamy, Pugazhendhi Vijayaraman
{"title":"How to Implant His Bundle and Left Bundle Pacing Leads: Tips and Pearls.","authors":"Shunmuga Sundaram Ponnusamy,&nbsp;Pugazhendhi Vijayaraman","doi":"10.15420/cfr.2021.04","DOIUrl":"https://doi.org/10.15420/cfr.2021.04","url":null,"abstract":"<p><p>Cardiac pacing is the treatment of choice for the management of patients with bradycardia. Although right ventricular apical pacing is the standard therapy, it is associated with an increased risk of pacing-induced cardiomyopathy and heart failure. Physiological pacing using His bundle pacing and left bundle branch pacing has recently evolved as the preferred alternative pacing option. Both His bundle pacing and left bundle branch pacing have also demonstrated significant efficacy in correcting left bundle branch block and achieving cardiac resynchronisation therapy. In this article, the authors review the implantation tools and techniques to perform conduction system pacing.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e13"},"PeriodicalIF":0.0,"publicationDate":"2021-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/6b/cfr-07-e13.PMC8383140.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39371866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Unknown Risks of Transplantation in Adults with Congenital Heart Disease. 成人先天性心脏病移植的未知风险。
Cardiac Failure Review Pub Date : 2021-08-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.09
Aniket S Rali, Angela Weingarten, Emily Sandhaus, Richa Gupta, Allman Rollins, David Bichell, Nhue Do, D Marshall Brinkley, Kelly H Schlendorf, Daniel Freno, Keki Balsara, Jonathan N Menachem
{"title":"Unknown Risks of Transplantation in Adults with Congenital Heart Disease.","authors":"Aniket S Rali,&nbsp;Angela Weingarten,&nbsp;Emily Sandhaus,&nbsp;Richa Gupta,&nbsp;Allman Rollins,&nbsp;David Bichell,&nbsp;Nhue Do,&nbsp;D Marshall Brinkley,&nbsp;Kelly H Schlendorf,&nbsp;Daniel Freno,&nbsp;Keki Balsara,&nbsp;Jonathan N Menachem","doi":"10.15420/cfr.2021.09","DOIUrl":"https://doi.org/10.15420/cfr.2021.09","url":null,"abstract":"","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e14"},"PeriodicalIF":0.0,"publicationDate":"2021-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e8/8f/cfr-07-e14.PMC8383139.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39371867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation and Management of Heart Block After Transcatheter Aortic Valve Replacement. 经导管主动脉瓣置换术后心脏传导阻滞的评价与处理。
Cardiac Failure Review Pub Date : 2021-07-27 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.05
Anthony J Mazzella, Sameer Arora, Michael J Hendrickson, Mason Sanders, John P Vavalle, Anil K Gehi
{"title":"Evaluation and Management of Heart Block After Transcatheter Aortic Valve Replacement.","authors":"Anthony J Mazzella,&nbsp;Sameer Arora,&nbsp;Michael J Hendrickson,&nbsp;Mason Sanders,&nbsp;John P Vavalle,&nbsp;Anil K Gehi","doi":"10.15420/cfr.2021.05","DOIUrl":"https://doi.org/10.15420/cfr.2021.05","url":null,"abstract":"<p><p>Transcatheter aortic valve replacement (TAVR) has developed substantially since its inception. Improvements in valve design, valve deployment technologies, preprocedural imaging and increased operator experience have led to a gradual decline in length of hospitalisation after TAVR. Despite these advances, the need for permanent pacemaker implantation for post-TAVR high-degree atrioventricular block (HAVB) has persisted and has well-established risk factors which can be used to identify patients who are at high risk and advise them accordingly. While most HAVB occurs within 48 hours of the procedure, there is a growing number of patients developing HAVB after initial hospitalisation for TAVR due to the trend for early discharge from hospital. Several observation and management strategies have been proposed. This article reviews major known risk factors for HAVB after TAVR, discusses trends in the timing of HAVB after TAVR and reviews some management strategies for observing transient HAVB after TAVR.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e12"},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/19/cfr-07-e12.PMC8353545.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39306121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure. 碳水化合物抗原125:心衰中充血和炎症十字路口的生物标志物。
Cardiac Failure Review Pub Date : 2021-06-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.22
Marko Kumric, Tina Ticinovic Kurir, Josko Bozic, Duska Glavas, Tina Saric, Bjørnar Marcelius, Domenico D'Amario, Josip A Borovac
{"title":"Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure.","authors":"Marko Kumric,&nbsp;Tina Ticinovic Kurir,&nbsp;Josko Bozic,&nbsp;Duska Glavas,&nbsp;Tina Saric,&nbsp;Bjørnar Marcelius,&nbsp;Domenico D'Amario,&nbsp;Josip A Borovac","doi":"10.15420/cfr.2021.22","DOIUrl":"https://doi.org/10.15420/cfr.2021.22","url":null,"abstract":"<p><p>Because heart failure (HF) is more lethal than some of the common malignancies in the general population, such as prostate cancer in men and breast cancer in women, there is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, especially concerning congestion, the most common reason for the hospitalisation of patients with worsening of HF. Furthermore, despite diuretics being the mainstay of treatment for volume overload in HF patients, no randomised trials have shown the mortality benefits of diuretics in HF patients, and appropriate diuretic titration strategies in this population are unclear. Recently, carbohydrate antigen (CA) 125, a well-established marker of ovarian cancer, emerged as both a prognostic indicator and a guide in tailoring decongestion therapy for patients with HF. Hence, in this review the authors present the molecular background regarding the role of CA125 in HF and address valuable clinical aspects regarding the relationship of CA125 with both prognosis and therapeutic management in HF.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e19"},"PeriodicalIF":0.0,"publicationDate":"2021-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/b9/cfr-07-e19.PMC8674624.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39872159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
The Future of Telemedicine in the Management of Heart Failure Patients. 远程医疗在心力衰竭患者管理中的未来。
IF 4.2
Cardiac Failure Review Pub Date : 2021-05-28 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.32
José Silva-Cardoso, José Ramón González Juanatey, Josep Comin-Colet, José Maria Sousa, Ana Cavalheiro, Emília Moreira
{"title":"The Future of Telemedicine in the Management of Heart Failure Patients.","authors":"José Silva-Cardoso, José Ramón González Juanatey, Josep Comin-Colet, José Maria Sousa, Ana Cavalheiro, Emília Moreira","doi":"10.15420/cfr.2020.32","DOIUrl":"10.15420/cfr.2020.32","url":null,"abstract":"<p><p>Telemedicine (TM) is potentially a way of escalating heart failure (HF) multidisciplinary integrated care. Despite the initial efforts to implement TM in HF management, we are still at an early stage of its implementation. The coronavirus disease 2019 pandemic led to an increased utilisation of TM. This tendency will probably remain after the resolution of this threat. Face-to-face medical interventions are gradually transitioning to the virtual setting by using TM. TM can improve healthcare accessibility and overcome geographic inequalities. It promotes healthcare system efficiency gains, and improves patient self-management and empowerment. In cooperation with human intervention, artificial intelligence can enhance TM by helping to deal with the complexities of multicomorbidity management in HF, and will play a relevant role towards a personalised HF patient approach. Artificial intelligence-powered/telemedical/heart team/multidisciplinary integrated care may be the next step of HF management. In this review, the authors analyse TM trends in the management of HF patients and foresee its future challenges within the scope of HF multidisciplinary integrated care.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e11"},"PeriodicalIF":4.2,"publicationDate":"2021-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/de/34/cfr-07-e11.PMC8201465.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39244542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab. 利妥昔单抗治疗德维克综合征患者致死性肠病毒相关性心肌炎
Cardiac Failure Review Pub Date : 2021-05-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.33
Ava Diarra, Guillaume Gantois, Mouna Lazrek, Basile Verdier, Vincent Elsermans, Hélène Zephir, Benjamin Longère, Xristos Gkizas, Céline Goeminne, Gilles Lemesle, Francis Juthier, Johana Bene, David Launay, Romain Dubois, Sandrine Morell-Dubois, Fanny Vuotto, Anne-Laure Piton
{"title":"Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab.","authors":"Ava Diarra,&nbsp;Guillaume Gantois,&nbsp;Mouna Lazrek,&nbsp;Basile Verdier,&nbsp;Vincent Elsermans,&nbsp;Hélène Zephir,&nbsp;Benjamin Longère,&nbsp;Xristos Gkizas,&nbsp;Céline Goeminne,&nbsp;Gilles Lemesle,&nbsp;Francis Juthier,&nbsp;Johana Bene,&nbsp;David Launay,&nbsp;Romain Dubois,&nbsp;Sandrine Morell-Dubois,&nbsp;Fanny Vuotto,&nbsp;Anne-Laure Piton","doi":"10.15420/cfr.2020.33","DOIUrl":"https://doi.org/10.15420/cfr.2020.33","url":null,"abstract":"<p><p>Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses - in particular, the Coxsackie B viruses - are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e09"},"PeriodicalIF":0.0,"publicationDate":"2021-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/7e/cfr-07-e09.PMC8135016.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39019202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Hyperkalaemia in Heart Failure. 心力衰竭的高钾血症。
Cardiac Failure Review Pub Date : 2021-05-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.29
Umar Ismail, Kiran Sidhu, Shelley Zieroth
{"title":"Hyperkalaemia in Heart Failure.","authors":"Umar Ismail,&nbsp;Kiran Sidhu,&nbsp;Shelley Zieroth","doi":"10.15420/cfr.2020.29","DOIUrl":"https://doi.org/10.15420/cfr.2020.29","url":null,"abstract":"<p><p>Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin-angiotensin-aldosterone system (RAAS) inhibitors and angiotensin-neprilysin inhibitors being the cornerstone of medical therapy. Patients living with HF often have other comorbidities, such as diabetes and chronic kidney disease, which predispose to hyperkalaemia. Until now, we have not had any reliable or tolerable therapies for the treatment of hyperkalaemia to facilitate implementation or achievement of target doses of RAAS inhibition. Patiromer sorbitex calcium and sodium zirconium cyclosilicate are two novel potassium-binding resins that have shown promise in the management of patients predisposed to developing recurrent hyperkalaemia, and their use may allow for further optimisation of guideline directed medical therapy.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e10"},"PeriodicalIF":0.0,"publicationDate":"2021-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/35/cfr-07-e10.PMC8150383.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39068492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Digital Health: Implications for Heart Failure Management. 数字健康:对心衰管理的影响。
IF 4.2
Cardiac Failure Review Pub Date : 2021-05-11 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.28
Arvind Singhal, Martin R Cowie
{"title":"Digital Health: Implications for Heart Failure Management.","authors":"Arvind Singhal, Martin R Cowie","doi":"10.15420/cfr.2020.28","DOIUrl":"10.15420/cfr.2020.28","url":null,"abstract":"<p><p>Digital health encompasses the use of information and communications technology and the use of advanced computing sciences in healthcare. This review covers the application of digital health in heart failure patients, focusing on teleconsultation, remote monitoring and apps and wearables, looking at how these technologies can be used to support care and improve outcomes. Interest in and use of these technologies, particularly teleconsultation, have been accelerated by the coronavirus disease 2019 pandemic. Remote monitoring of heart failure patients, to identify those patients at high risk of hospitalisation and to support clinical stability, has been studied with mixed results. Remote monitoring of pulmonary artery pressure has a consistent effect on reducing hospitalisation rates for patients with moderately severe symptoms and multiparameter monitoring shows promise for the future. Wearable devices and apps are increasingly used by patients for health and lifestyle support. Some wearable technologies have shown promise in AF detection, and others may be useful in supporting self-care and guiding prognosis, but more evidence is required to guide their optimal use. Support for patients and clinicians wishing to use these technologies is important, along with consideration of data validity and privacy and appropriate recording of decision-making.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e08"},"PeriodicalIF":4.2,"publicationDate":"2021-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/84/cfr-07-e08.PMC8135017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39019201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CardioMEMS Implantation Using Gadolinium-based Contrast Agent: A Case Report. 基于钆造影剂的心脏ems植入:1例报告。
Cardiac Failure Review Pub Date : 2021-04-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.03
Aniket S Rali, Lynne W Stevenson, Sandip K Zalawadiya
{"title":"CardioMEMS Implantation Using Gadolinium-based Contrast Agent: A Case Report.","authors":"Aniket S Rali,&nbsp;Lynne W Stevenson,&nbsp;Sandip K Zalawadiya","doi":"10.15420/cfr.2021.03","DOIUrl":"https://doi.org/10.15420/cfr.2021.03","url":null,"abstract":"<p><p>A 57-year-old woman with New York Heart Association Class III heart failure requiring multiple hospitalisations over the previous year presented for CardioMEMS implantation. Because of the patient's allergy history of anaphylaxis to iodine-based contrast agent she underwent the device implantation with gadolinium-based contrast agent (Magnevist), which was successful.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e07"},"PeriodicalIF":0.0,"publicationDate":"2021-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/d5/cfr-07-e07.PMC8076965.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38950467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. 舒比利/缬沙坦在心力衰竭和射血分数降低患者治疗过程中的基本原理和实际应用
Cardiac Failure Review Pub Date : 2021-04-05 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.25
Mauro Gori, James L Januzzi, Emilia D'Elia, Ferdinando L Lorini, Michele Senni
{"title":"Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction.","authors":"Mauro Gori,&nbsp;James L Januzzi,&nbsp;Emilia D'Elia,&nbsp;Ferdinando L Lorini,&nbsp;Michele Senni","doi":"10.15420/cfr.2020.25","DOIUrl":"https://doi.org/10.15420/cfr.2020.25","url":null,"abstract":"<p><p>Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril/valsartan is associated with improved outcomes compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and has a greater beneficial effect on myocardial reverse remodelling. Additionally, two recent trials have shown that sacubitril/valsartan is well-tolerated even in the acute HF setting, thus enabling a continuum of use in the patient's journey with HFrEF. This article summarises available data on the effectiveness and tolerability of sacubitril/valsartan in patients with HFrEF, and provides the clinician with practical insights to facilitate the use of this drug in every setting, with an emphasis on acute HF, hypotension, electrolyte imbalance and renal insufficiency.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e06"},"PeriodicalIF":0.0,"publicationDate":"2021-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/40/12/cfr-07-e06.PMC8054374.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38900264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信